Amedeo Smart

Free Medical Literature Service


 

Amedeo

Chronic Heart Failure

  Free Subscription

Articles published in
Cardiovasc Res
    August 2021
  1. DAVIDSON SM, Padro T, Bollini S, Vilahur G, et al
    Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart.
    Cardiovasc Res. 2021;117:2161-2174.
    >> Share

  2. RICHARDS AM
    Proteomic probing for markers and mechanisms in Heart Failure.
    Cardiovasc Res. 2021 Aug 10. pii: 6347578. doi: 10.1093.
    >> Share

    July 2021
  3. ZHAO B, Bouchareb R, Lebeche D
    Resistin deletion protects against heart failure injury by targeting DNA damage response.
    Cardiovasc Res. 2021 Jul 29. pii: 6330773. doi: 10.1093.
    >> Share

  4. ABDELLATIF M, Lam CSP
    Scientists on the Spot: A fraction of wisdom on heart failure.
    Cardiovasc Res. 2021;117:e114-e115.
    >> Share

  5. MARKOUSIS-MAVROGENIS G, Tromp J, Ouwerkerk W, Fereirra JP, et al
    Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
    Cardiovasc Res. 2021 Jul 15. pii: 6321950. doi: 10.1093.
    >> Share

  6. DIEZ J, de Boer RA
    Management of cardiac fibrosis is the largest unmet medical need in heart failure Cardiac fibrosis in heart failure.
    Cardiovasc Res. 2021 Jul 9. pii: 6318397. doi: 10.1093.
    >> Share

  7. GRASSI G, Mancia G, Esler M
    CENTRAL AND PERIPHERAL SYMPATHETIC ACTIVATION IN HEART FAILURE.
    Cardiovasc Res. 2021 Jul 7. pii: 6317668. doi: 10.1093.
    >> Share

    June 2021
  8. ONODI Z, Ruppert M, Kucsera D, Sayour AA, et al
    AIM2-driven inflammasome activation in heart failure.
    Cardiovasc Res. 2021 Jun 12. pii: 6297397. doi: 10.1093.
    >> Share

  9. SANSONETTI M, De Windt LJ
    Non-coding RNAs in cardiac inflammation: key drivers in the pathophysiology of heart failure.
    Cardiovasc Res. 2021 Jun 7. pii: 6294284. doi: 10.1093.
    >> Share

  10. NAUMENKO N, Mutikainen M, Holappa L, Ruas JL, et al
    PGC-1alpha deficiency reveals sex-specific links between cardiac energy metabolism and EC-coupling during development of heart failure in mice.
    Cardiovasc Res. 2021 Jun 4. pii: 6292089. doi: 10.1093.
    >> Share

    May 2021

  11. Corrigendum to: Heart failure or heart success?
    Cardiovasc Res. 2021 May 18. pii: 6277376. doi: 10.1093.
    >> Share

    April 2021

  12. Retraction: Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure.
    Cardiovasc Res. 2021 Apr 22. pii: 6245632. doi: 10.1093.
    >> Share

  13. BOLLI R, Solankhi M, Tang XL, Kahlon A, et al
    Cell Therapy in Patients with Heart Failure: A Comprehensive Review and Emerging Concepts.
    Cardiovasc Res. 2021 Apr 19. pii: 6237881. doi: 10.1093.
    >> Share

    March 2021
  14. KARWI QG, Ho KL, Pherwani S, Ketema EB, et al
    Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
    Cardiovasc Res. 2021 Mar 30. pii: 6203809. doi: 10.1093.
    >> Share

  15. SELVARAJ S, Margulies KB
    Exogenous ketones in the healthy heart: the plot thickens.
    Cardiovasc Res. 2021;117:995-996.
    >> Share

  16. TAKAHARA S, Soni S, Maayah ZH, Ferdaoussi M, et al
    Ketone Therapy for Heart Failure: Current Evidence for Clinical Use.
    Cardiovasc Res. 2021 Mar 10. pii: 6168424. doi: 10.1093.
    >> Share

  17. CUOMO A, Pirozzi F, Tocchetti CG
    Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): lupus in fabula?
    Cardiovasc Res. 2021 Mar 5. pii: 6159769. doi: 10.1093.
    >> Share

    February 2021
  18. LUXAN G, Dimmeler S
    The vasculature: a therapeutic target in heart failure?
    Cardiovasc Res. 2021 Feb 23. pii: 6146925. doi: 10.1093.
    >> Share

  19. TERAMOTO K, Tromp J, Lam CSP
    Heart failure or heart success?
    Cardiovasc Res. 2021 Feb 13. pii: 6134544. doi: 10.1093.
    >> Share

  20. DE LUCIA C, Grisanti LA, Borghetti G, Piedepalumbo M, et al
    GRK5 contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure.
    Cardiovasc Res. 2021 Feb 9. pii: 6131786. doi: 10.1093.
    >> Share

    January 2021
  21. HEGYI B, Ko CY, Bossuyt J, Bers DM, et al
    Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycemia: reduced repolarization reserve, neurohormonal stimulation and heart failure exacerbate susceptibility.
    Cardiovasc Res. 2021 Jan 23. pii: 6105172. doi: 10.1093.
    >> Share

  22. CICCARELLI M, Dawson D, Falcao-Pires I, Giacca M, et al
    Reciprocal organ interactions during heart failure-a position paper from the ESC working group on myocardial function.
    Cardiovasc Res. 2021 Jan 22. pii: 6105178. doi: 10.1093.
    >> Share

  23. TOENNIS T, Kirchhof P
    Connecting the dots? Rate control, heart failure, and atrial fibrillation.
    Cardiovasc Res. 2021;117:336-337.
    >> Share

  24. PANENI F, Sciarretta S, Costantino S
    Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?
    Cardiovasc Res. 2021;117:343-345.
    >> Share

    November 2020
  25. MELI AC, Fischmeister R
    Scientists on the spot: Phosphodiesterases and heart failure.
    Cardiovasc Res. 2020 Nov 1. pii: 5952729. doi: 10.1093.
    >> Share

    October 2020
  26. NAKAMURA M, Odanovic N, Nakada Y, Dohi S, et al
    Dietary Carbohydrates Restriction Inhibits The Development Of Cardiac Hypertrophy And Heart Failure.
    Cardiovasc Res. 2020 Oct 18. pii: 5929700. doi: 10.1093.
    >> Share

  27. PANICO C, Kallikourdis M, Condorelli G
    Defining circulating mononuclear cells in heart failure through single-cell RNA sequencing: new insights for an old disease.
    Cardiovasc Res. 2020 Oct 13. pii: 5922371. doi: 10.1093.
    >> Share

  28. LANG NN, Dobbin SJH, Petrie MC
    Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial.
    Cardiovasc Res. 2020;116:e152-e155.
    >> Share

    September 2020
  29. WITHAAR C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, et al
    The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of Heart Failure with Preserved Ejection Fraction.
    Cardiovasc Res. 2020 Sep 1. pii: 5900261. doi: 10.1093.
    >> Share

    August 2020
  30. PERROTTA S, Carnevale D
    A neuro-humoral activation of RAAS in endothelial dysfunction modulating immunity in heart failure.
    Cardiovasc Res. 2020 Aug 4. pii: 5880579. doi: 10.1093.
    >> Share

  31. BERTERO E, Stork S, Maack C
    REPORT-HF reveals global inequalities in health care provision and prognosis of patients with acute heart failure.
    Cardiovasc Res. 2020;116:e112-e114.
    >> Share

    July 2020
  32. NAGUEH SF
    Heart Failure with Preserved Ejection Fraction: Insights into Diagnosis and Pathophysiology.
    Cardiovasc Res. 2020 Jul 27. pii: 5876832. doi: 10.1093.
    >> Share

  33. SCHIATTARELLA GG, Rodolico D, Hill JA
    Metabolic Inflammation in Heart Failure with Preserved Ejection Fraction.
    Cardiovasc Res. 2020 Jul 14. pii: 5871499. doi: 10.1093.
    >> Share

  34. MELI AC, de Tombe P
    Scientists on the Spot: Myocardium and myofilaments.
    Cardiovasc Res. 2020;116:e96-e97.
    >> Share

    May 2020
  35. KOLIJN D, Pabel S, Tian Y, Lodi M, et al
    Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Galpha oxidation.
    Cardiovasc Res. 2020 May 12. pii: 5836298. doi: 10.1093.
    >> Share

    April 2020
  36. ABPLANALP WT, John D, Cremer S, Assmus B, et al
    Single cell RNA sequencing reveals profound changes in circulating immune cells in patients with heart failure.
    Cardiovasc Res. 2020 Apr 20. pii: 5822866. doi: 10.1093.
    >> Share

  37. PACKER M
    Critical Examination of Mechanisms Underlying the Reduction in Heart Failure Events With SGLT2 Inhibitors: Identification of a Molecular Link Between Their Actions to Stimulate Erythrocytosis and to Alleviate Cellular Stress.
    Cardiovasc Res. 2020 Apr 3. pii: 5815560. doi: 10.1093.
    >> Share

    March 2020
  38. RADEMAKER MT, Scott NJA, Koh CY, Kini RM, et al
    Natriuretic peptide analogues with distinct vasodilatory or renal activity: Integrated effects in health and experimental heart failure.
    Cardiovasc Res. 2020 Mar 13. pii: 5804984. doi: 10.1093.
    >> Share

  39. VAN BERLO JH, Garry DJ
    Hearts and Hands: the good, the bad, and the ugly.
    Cardiovasc Res. 2020;116:470-472.
    >> Share

  40. VOLLAND C, Schott P, Didie M, Manner J, et al
    Control of p21Cip by BRCA1-associated protein is critical for cardiomyocyte cell cycle progression and survival.
    Cardiovasc Res. 2020;116:592-604.
    >> Share

    February 2020
  41. MOLITOR M, Rudi WS, Garlapati V, Finger S, et al
    Nox2+ Myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1.
    Cardiovasc Res. 2020 Feb 20. pii: 5741408. doi: 10.1093.
    >> Share

    January 2020
  42. CAMICI PG, Tschope C, Carli MFD, Rimoldi O, et al
    Coronary microvascular dysfunction in hypertrophy and heart failure.
    Cardiovasc Res. 2020 Jan 30. pii: 5718012. doi: 10.1093.
    >> Share

  43. ZHANG D, Tu H, Wang C, Cao L, et al
    Inhibition of N-type calcium channels in cardiac sympathetic neurons attenuates ventricular arrhythmogenesis in heart failure.
    Cardiovasc Res. 2020 Jan 29. pii: 5717428. doi: 10.1093.
    >> Share

  44. VERMA S
    The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
    Cardiovasc Res. 2020;116:e8-e10.
    >> Share

  45. COHEN-SOLAL A, Logeart D
    Is the glass half full or half empty after PARAGON-HF?
    Cardiovasc Res. 2020;116:e5-e7.
    >> Share

  46. CHEN MP, Kiduko SA, Saad NS, Canan BD, et al
    Stretching single titin molecules from failing human hearts reveals titin's role in blunting cardiac kinetic reserve.
    Cardiovasc Res. 2020;116:127-137.
    >> Share

    November 2019
  47. FILIPPATOS G, Farmakis D
    A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
    Cardiovasc Res. 2019;115:e140-e142.
    >> Share

    October 2019
  48. SACK MN
    The Enigma of Anti-Inflammatory Therapy for the Management of Heart Failure.
    Cardiovasc Res. 2019 Oct 30. pii: 5610071. doi: 10.1093.
    >> Share

  49. BILCHICK K, Kothari H, Narayan A, Garmey J, et al
    Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1beta in heart failure.
    Cardiovasc Res. 2019 Oct 15. pii: 5585796. doi: 10.1093.
    >> Share

  50. ANTONIADES C, Condorelli G
    Scientists on the Spot: non-coding RNAs and heart failure.
    Cardiovasc Res. 2019 Oct 9. pii: 5584268. doi: 10.1093.
    >> Share

    September 2019
  51. DOCHERTY KF, McMurray JJV
    PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
    Cardiovasc Res. 2019 Sep 8. pii: 5565262. doi: 10.1093.
    >> Share

    August 2019
  52. SOBANSKI PZ, Alt-Epping B, Currow DC, Goodlin SJ, et al
    Palliative Care for people living with heart failure - European Association for Palliative Care Task Force expert position statement.
    Cardiovasc Res. 2019 Aug 6. pii: 5544269. doi: 10.1093.
    >> Share

    July 2019
  53. PELLICORI P, Zhang J, Cuthbert J, Urbinati A, et al
    High sensitivity C-Reactive Protein in Chronic Heart Failure: Patient Characteristics, Phenotypes and Mode of Death.
    Cardiovasc Res. 2019 Jul 26. pii: 5539697. doi: 10.1093.
    >> Share

  54. FIRULLI BA, George R, Harkin J, Toolan KP, et al
    HAND1 loss-of-function within the embryonic myocardium reveals survivable congenital cardiac defects and adult heart failure.
    Cardiovasc Res. 2019 Jul 9. pii: 5529958. doi: 10.1093.
    >> Share

    June 2019
  55. RIEHLE C, Bauersachs J
    Small Animal Models of Heart Failure.
    Cardiovasc Res. 2019 Jun 27. pii: 5523845. doi: 10.1093.
    >> Share

  56. BERTERO E, Maack C
    The Partial AdeNosine A1 receptor agonist in patients with Chronic Heart failure and preserved Ejection fraction (PANACHE) trial.
    Cardiovasc Res. 2019 Jun 10. pii: 5513228. doi: 10.1093.
    >> Share

    May 2019
  57. KONEMANN S, Sartori LV, Gross S, Hadlich S, et al
    Cardio-protective effect of the secretome of Sca-1+ and Sca-1- cells in heart failure - not equal, but equally important?
    Cardiovasc Res. 2019 May 22. pii: 5497483. doi: 10.1093.
    >> Share

  58. KONDO H, Takahashi N
    Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
    Cardiovasc Res. 2019;115:e54-e57.
    >> Share

    March 2019
  59. ESFANDIARY A, Kutsche H, Schreckenberg R, Weber M, et al
    Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing.
    Cardiovasc Res. 2019 Mar 8. pii: 5372345. doi: 10.1093.
    >> Share

  60. DE KLEIJN DPV, Chong SY, Wang X, Yatim SMJM, et al
    Toll-like Receptor 7 Deficiency Promotes Survival and Reduces Adverse Left Ventricular Remodeling After Myocardial Infarction.
    Cardiovasc Res. 2019 Mar 4. pii: 5369232. doi: 10.1093.
    >> Share

    February 2019
  61. NGUYEN QT, Jalloul Nsaibia M, Sirois MG, Calderone A, et al
    PBI-4050 Reduces Pulmonary Hypertension, Lung fibrosis and Right Ventricular Dysfunction in Heart Failure.
    Cardiovasc Res. 2019 Feb 7. pii: 5308607. doi: 10.1093.
    >> Share

  62. MEIJERS WC, de Boer RA
    Common risk factors for heart failure and cancer.
    Cardiovasc Res. 2019 Feb 4. pii: 5306334. doi: 10.1093.
    >> Share

    January 2019
  63. ENDOH M
    SERCA in heterogeneity of diastolic dysfunction in post-infarction heart failure with reduced ejection fraction.
    Cardiovasc Res. 2019 Jan 31. pii: 5305030. doi: 10.1093.
    >> Share

  64. LIN H, Li Y, Zhu H, Wang Q, et al
    Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of beta-catenin.
    Cardiovasc Res. 2019 Jan 24. pii: 5300057. doi: 10.1093.
    >> Share

  65. MADONNA R, Van Laake LW, Botker HE, Davidson SM, et al
    ESC Working Group on Cellular Biology of the Heart: Tissue Engineering and Cell-Based Therapies for Cardiac Repair in Ischemic Heart Disease and Heart Failure.
    Cardiovasc Res. 2019 Jan 17. pii: 5292411. doi: 10.1093.
    >> Share

  66. NARUSE G, Kanamori H, Yoshida A, Minatoguchi S, et al
    The Intestine Responds to Heart Failure by Enhanced Mitochondrial Fusion through Glucagon-like Peptide-1 Signaling.
    Cardiovasc Res. 2019 Jan 10. pii: 5284909. doi: 10.1093.
    >> Share

  67. SINGH AP, Umbarkar P, Guo Y, Force T, et al
    Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration.
    Cardiovasc Res. 2019;115:20-30.
    >> Share

  68. SURINKAEW S, Aflaki M, Takawale A, Chen Y, et al
    Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling.
    Cardiovasc Res. 2019;115:94-106.
    >> Share

  69. GRUND A, Szaroszyk M, Doppner JK, Malek Mohammadi M, et al
    A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
    Cardiovasc Res. 2019;115:71-82.
    >> Share

    December 2018
  70. ZHANG J, Sheng J, Dong L, Xu Y, et al
    Cardiomyocyte-specific loss of RMP causes myocardial dysfunction and heart failure.
    Cardiovasc Res. 2018 Dec 24. pii: 5258468. doi: 10.1093.
    >> Share

  71. MICKAEL C, Lee MH, Gu S, Graham BB, et al
    Comparing pulmonary hypertension severity between rat strains suggests right ventricle NK cells are protective.
    Cardiovasc Res. 2018 Dec 4. pii: 5229543. doi: 10.1093.
    >> Share

    October 2018
  72. SUEN CM, Chaudhary KR, Deng Y, Jiang B, et al
    Fischer rats exhibit maladaptive structural and molecular right ventricular remodelling in severe pulmonary hypertension: a genetically prone model for right heart failure.
    Cardiovasc Res. 2018 Oct 24. pii: 5144198. doi: 10.1093.
    >> Share

  73. ROE AT, Ruud M, Espe EK, Manfra O, et al
    Regional diastolic dysfunction in post-infarction heart failure: role of local mechanical load and SERCA expression.
    Cardiovasc Res. 2018 Oct 23. pii: 5142689. doi: 10.1093.
    >> Share

    September 2018
  74. SCHLOSS MJ, Horckmans M, Guillamat-Prats R, Hering D, et al
    2-arachidonoylglycerol mobilizes myeloid cells and worsens heart function after acute myocardial infarction.
    Cardiovasc Res. 2018 Sep 28. pii: 5115994. doi: 10.1093.
    >> Share

    August 2018
  75. COPPINI R, Ferrantini C
    NaV1.8: a novel contributor to cardiac arrhythmogenesis in heart failure.
    Cardiovasc Res. 2018 Aug 29. pii: 5086354. doi: 10.1093.
    >> Share

  76. BASTUG-OZEL Z, Wright PT, Kraft AE, Pavlovic D, et al
    Heart failure leads to altered beta2-adrenoceptor/cAMP dynamics in the sarcolemmal phospholemman/Na,K ATPase microdomain: Bastug et al. Phospholemman cAMP microdomain.
    Cardiovasc Res. 2018 Aug 27. pii: 5079901. doi: 10.1093.
    >> Share

    July 2018
  77. POL AV, Gil A, Tromp J, Sillje HHW, et al
    OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.
    Cardiovasc Res. 2018 Jul 19. pii: 5056075. doi: 10.1093.
    >> Share

  78. PANAHI M, Papanikolaou A, Torabi A, Zhang JG, et al
    Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition.
    Cardiovasc Res. 2018 Jul 14. pii: 5054000. doi: 10.1093.
    >> Share

  79. DOBREV D, Fender AC, Wehrens XHT
    Pro-arrhythmic RyR2 channels in heart failure: do their localisation and mechanism of activation really matter?
    Cardiovasc Res. 2018 Jul 3. pii: 5048462. doi: 10.1093.
    >> Share

    June 2018
  80. IDRES S, Perrin G, Domergue V, Lefebvre F, et al
    Contribution of BKCa channels to vascular tone regulation by PDE3 and PDE4 is lost in heart failure.
    Cardiovasc Res. 2018 Jun 23. pii: 5043286. doi: 10.1093.
    >> Share

  81. KARKKAINEN O, Tuomainen T, Mutikainen M, Lehtonen M, et al
    Heart specific PGC-1alpha deletion identifies metabolome of cardiac restricted metabolic heart failure.
    Cardiovasc Res. 2018 Jun 20. pii: 5040494. doi: 10.1093.
    >> Share

  82. NATTEL S
    Catheter ablation of atrial fibrillation and outcomes in heart failure patients: seeking the treasure in the CASTLE.
    Cardiovasc Res. 2018;114:e50-e52.
    >> Share

    April 2018
  83. VAN DER ENDE MY, Said MA, van Veldhuisen DJ, Verweij N, et al
    Genome Wide Studies of Heart Failure and Endophenotypes: lessons learned and future directions.
    Cardiovasc Res. 2018 Apr 18. pii: 4975446. doi: 10.1093.
    >> Share

  84. DRIES E, Santiago DJ, Gilbert G, Lenaerts I, et al
    Hyperactive ryanodine receptors in human heart failure and ischemic cardiomyopathy reside outside of couplons.
    Cardiovasc Res. 2018 Apr 14. pii: 4970798. doi: 10.1093.
    >> Share

  85. BORGOGNONE A, Shantsila E, Worrall SM, Prompunt E, et al
    Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation.
    Cardiovasc Res. 2018 Apr 12. pii: 4969512. doi: 10.1093.
    >> Share

    March 2018
  86. DE ROSA M, Gambardella J, Shu J, Santulli G, et al
    Dietary Fat is a Key Determinant in Balancing Mitochondrial Dynamics in Heart Failure: A Novel Mechanism Underlying the Obesity Paradox.
    Cardiovasc Res. 2018 Mar 22. pii: 4951453. doi: 10.1093.
    >> Share

    November 2017
  87. FLORIJN BW, Bijkerk R, van der Veer E, van Zonneveld AJ, et al
    Gender and cardiovascular disease: Are sex-biased miRNA networks a driving force behind heart failure with preserved ejection fraction in women?
    Cardiovasc Res. 2017 Nov 24. pii: 4657087. doi: 10.1093.
    >> Share

  88. ZIEGLER KA, Ahles A, Wille T, Kerler J, et al
    Local sympathetic denervation attenuates myocardial inflammation and improves cardiac function after myocardial infarction in mice.
    Cardiovasc Res. 2017 Nov 24. pii: 4657089. doi: 10.1093.
    >> Share

    September 2017
  89. RIPPLINGER CM
    From drugs to devices and back again: chemical vagal nerve stimulation for the treatment of heart failure.
    Cardiovasc Res. 2017;113:1270-1272.
    >> Share

    July 2017
  90. FRASER AG, Gillebert TC, Leite-Moreira AF
    Ventricular-arterial coupling in heart failure with preserved ejection fraction: the devil is in the details.
    Cardiovasc Res. 2017;113:844-846.
    >> Share

    June 2017
  91. SCHOBESBERGER S, Wright P, Tokar S, Bhargava A, et al
    T-tubule remodelling disturbs localized beta2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure.
    Cardiovasc Res. 2017;113:770-782.
    >> Share

    May 2017
  92. ABDURRACHIM D, Nabben M, Hoerr V, Kuhlmann MT, et al
    Diabetic db/db mice do not develop heart failure upon pressure overload: A longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations.
    Cardiovasc Res. 2017 May 26. doi: 10.1093.
    >> Share

  93. VILLALBA-ORERO M, Lopez-Olaneta MM, Gonzalez-Lopez E, Padron-Barthe L, et al
    Lung ultrasound as a translational approach for non-invasive assessment of heart failure with reduced or preserved ejection fraction in mice.
    Cardiovasc Res. 2017 May 4. doi: 10.1093.
    >> Share

  94. GARROTT K, Dyavanapalli J, Cauley E, Kate Dwyer M, et al
    Chronic activation of hypothalamic oxytocin neurons improves cardiac function during left ventricular hypertrophy-induced heart failure.
    Cardiovasc Res. 2017 May 2. doi: 10.1093.
    >> Share

  95. LI J, Yousefi K, Ding W, Singh J, et al
    Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure.
    Cardiovasc Res. 2017;113:633-643.
    >> Share

  96. NONHOFF J, Ricke-Hoch M, Mueller M, Stapel B, et al
    Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.
    Cardiovasc Res. 2017;113:598-608.
    >> Share

  97. HAUSENLOY DJ, Garcia-Dorado D, Botker HE, Davidson SM, et al
    Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart.
    Cardiovasc Res. 2017;113:564-585.
    >> Share

    April 2017
  98. CROSSMAN DJ, Shen X, Jullig M, Munro M, et al
    Increased collagen within the transverse tubules in human heart failure.
    Cardiovasc Res. 2017 Apr 20. doi: 10.1093.
    >> Share

  99. PEREZ DEL VILLAR C, Savvatis K, Lopez B, Kasner M, et al
    Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction.
    Cardiovasc Res. 2017 Apr 11. doi: 10.1093.
    >> Share

    March 2017
  100. SATO T, Sato C, Kadowaki A, Watanabe H, et al
    ELABELA - APJ axis protects from pressure overload heart failure and Angiotensin II-induced cardiac damage.
    Cardiovasc Res. 2017 Mar 23. doi: 10.1093.
    >> Share

    February 2017
  101. LI J, Yousefi K, Ding W, Singh J, et al
    Osteopontin RNA Aptamer Can Prevent and Reverse Pressure Overload-Induced Heart Failure.
    Cardiovasc Res. 2017 Feb 1. doi: 10.1093.
    >> Share

  102. GRECO S, Zaccagnini G, Fuschi P, Voellenkle C, et al
    Increased Bace1-As Long Noncoding Rna And beta-Amyloid Levels In Heart Failure.
    Cardiovasc Res. 2017 Feb 1. doi: 10.1093.
    >> Share

  103. ELIA L, Quintavalle M, Condorelli G
    Circular RNAs and heart failure: new players for an old disease.
    Cardiovasc Res. 2017 Feb 1. doi: 10.1093.
    >> Share

    January 2017
  104. NONHOFF J, Ricke-Hoch M, Mueller M, Stapel B, et al
    Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.
    Cardiovasc Res. 2017 Jan 20. pii: cvw245. doi: 10.1093.
    >> Share

    November 2016
  105. LI L, Li J, Drum BM, Chen Y, et al
    Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve.
    Cardiovasc Res. 2016.
    >> Share

    July 2016
  106. LIU L, An X, Li Z, Song Y, et al
    The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy.
    Cardiovasc Res. 2016;111:56-65.
    >> Share

  107. SCHEID LM, Mosqueira M, Hein S, Kossack M, et al
    Essential light chain S195 phosphorylation is required for cardiac adaptation under physical stress.
    Cardiovasc Res. 2016;111:44-55.
    >> Share

    June 2016
  108. HILLE S, Dierck F, Kuhl C, Sosna J, et al
    Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
    Cardiovasc Res. 2016;110:381-94.
    >> Share

    May 2016
  109. KOOIJ V, Viswanathan MC, Lee DI, Rainer PP, et al
    Profilin modulates sarcomeric organization and mediates cardiomyocyte hypertrophy.
    Cardiovasc Res. 2016;110:238-48.
    >> Share

    January 2016
  110. GOH KY, Qu J, Hong H, Liu T, et al
    Impaired mitochondrial network excitability in failing guinea-pig cardiomyocytes.
    Cardiovasc Res. 2016;109:79-89.
    >> Share

    December 2015
  111. KUMAGAI S, Nakayama H, Fujimoto M, Honda H, et al
    Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction.
    Cardiovasc Res. 2015.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016